Ensysce Biosciences Q3 2024 GAAP EPS $0.07 Beats $(0.29) Estimate, Sales $3.40M Beat $250.00K Estimate

Benzinga11-13

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.29) by 124.14 percent. The company reported quarterly sales of $3.40 million which beat the analyst consensus estimate of $250.00 thousand by 1.26K percent. This is a 680.93 percent increase over sales of $435.38 thousand the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment